Table 2.
Results of anthelmintic activity of 4-aminoantipyrine derivatives 4(a–h).
| Test Compds | 12.5 mg/mL | 25 mg/mL | 50 mg/mL | 100 mg/mL | 150 mg/mL | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Time of paralysis (min.) | Time of death (min.) |
Time of paralysis (min.) |
Time of death (min.) |
Time of paralysis (min.) |
Time of death (min.) |
Time of paralysis (min.) |
Time of death (min.) |
Time of paralysis (min.) |
Time of death (min.) |
|
| Control | — | — | — | — | — | — | — | — | — | — |
| ALB | 21 ± 0.6 | 22 ± 0.5 | 18 ± 0.4* | 19 ± 0.6 | 15 ± 1.0 | 17 ± 0.8 | 13 ± 1.2 | 14 ± 0.6* | 10 ± 0.5 | 10 ± 1.8* |
| 4a | 22 ± 1.4 | 23 ± 0.5 | 19 ± 1.5 | 20 ± 0.7* | 16 ± 1.0 | 17 ± 0.6 | 14 ± 0.7* | 15 ± 1.3* | 11 ± 0.5 | 11 ± 1.0* |
| 4b | 23 ± 1.5 | 23 ± 1.3* | 20 ± 2.1* | 21 ± 2.3 | 18 ± 1.2 | 20 ± 1.0 | 15 ± 1.2* | 16 ± 1.7 | 12 ± 0.5 | 12 ± 0.3 |
| 4c | 30 ± 0.6 | 31 ± 0.5* | 28 ± 1.3 | 29 ± 1.0* | 26 ± 0.7* | 27 ± 0.9 | 22 ± 0.5 | 23 ± 0.7 | 20 ± 1.2* | 19 ± 0.7 |
| 4d | 39 ± 0.9 | 42 ± 1.5 | 37 ± 1.4 | 40 ± 1.2 | 35 ± 1.3 | 35 ± 1.2 | 33 ± 0.6 | 34 ± 0.7 | 31 ± 0.8 | 32 ± 0.4 |
| 4e | 24 ± 0.8* | 24 ± 1.3 | 21 ± 1.3 | 22 ± 0.1* | 17 ± 0.6 | 17 ± 1.6* | 14 ± 0.7 | 15 ± 1.0 | 12 ± 0.8* | 12 ± 0.2 |
| 4f | 30 ± 1.0* | 30 ± 0.6 | 29 ± 0.3 | 30 ± 1.0 | 27 ± 1.2 | 28 ± 0.6* | 24 ± 0.5 | 25 ± 1.2 | 20 ± 1.5 | 21 ±1.2 |
| 4g | 21 ± 0.4 | 23 ± 0.7 | 19 ± 0.3 | 19 ± 1.1 | 16 ± 1.0 | 17 ± 0.6 | 13 ± 1.7 | 14 ± 0.6* | 12 ± 1.0 | 12 ± 1.2 |
| 4h | 29 ± 0.3 | 30 ± 0.5 | 26 ± 1.3 | 27 ± 1.0 | 24 ± 0.2* | 24 ± 0.6* | 21 ± 0.7 | 22 ± 0.4 | 18 ± 1.0 | 19 ± 1.2* |
Standard drug, Albendazole (ALB), was used at 10 mg/mL; “—” indicates absence of activity in 24 h of administration. *Significantly different from ALB at P < 0.05.